Vincent Joerg - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Vincent Joerg

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Frontiers in Immunology|January 25, 2024

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver diseaseLorenz Kocheise, Ignazio Piseddu, Joscha Vonderlin, et al.

Journal of Experimental & Clinical Cancer Research : CR|November 8, 2024

Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapyJoao Gorgulho, Sven H Loosen, Ramsha Masood, et al.

Hepatology Communications|October 27, 2023

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational studyVincent Joerg, Bernhard Scheiner, Antonio D Alessio, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Frontiers in Immunology|January 25, 2024

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver diseaseLorenz Kocheise, Ignazio Piseddu, Joscha Vonderlin, et al.

Journal of Experimental & Clinical Cancer Research : CR|November 8, 2024

Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapyJoao Gorgulho, Sven H Loosen, Ramsha Masood, et al.

Hepatology Communications|October 27, 2023

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational studyVincent Joerg, Bernhard Scheiner, Antonio D Alessio, et al.

Pageof 2